HomeCompareMGIC vs PFE

MGIC vs PFE: Dividend Comparison 2026

MGIC yields 5.81% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.5K in total portfolio value· pulled ahead in Year 9
10 years
MGIC
MGIC
● Live price
5.81%
Share price
$17.38
Annual div
$1.01
5Y div CAGR
-33.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$10.95
Full MGIC calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — MGIC vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGICPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGIC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MGIC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGIC
Annual income on $10K today (after 15% tax)
$493.96/yr
After 10yr DRIP, annual income (after tax)
$9.31/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $23,119.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGIC + PFE for your $10,000?

MGIC: 50%PFE: 50%
100% PFE50/50100% MGIC
Portfolio after 10yr
$36.3K
Annual income
$13,610.75/yr
Blended yield
37.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MGIC
Analyst Ratings
2
Buy
2
Hold
2
Sell
Consensus: Buy
Price Target
$18.50
+6.4% upside vs current
Range: $15.00 — $22.00
Altman Z
3.6
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGIC buys
0
PFE buys
0
No recent congressional trades found for MGIC or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGICPFE
Forward yield5.81%6.20%
Annual dividend / share$1.01$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-33.4%13.2%
Portfolio after 10y$21.6K$51.1K
Annual income after 10y$10.95$27,210.54
Total dividends collected$1.2K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$18.50$27.50

Year-by-year: MGIC vs PFE ($10,000, DRIP)

YearMGIC PortfolioMGIC Income/yrPFE PortfolioPFE Income/yrGap
1$11,087$387.03$9,161$701.38+$1.9KMGIC
2$12,130$267.09$8,610$859.79+$3.5KMGIC
3$13,161$181.88$8,366$1,081.25+$4.8KMGIC
4$14,205$122.83$8,483$1,405.66+$5.7KMGIC
5$15,282$82.52$9,084$1,907.24+$6.2KMGIC
6$16,407$55.26$10,418$2,732.78+$6.0KMGIC
7$17,593$36.93$13,007$4,193.56+$4.6KMGIC
8$18,849$24.64$18,010$7,005.87+$839.00MGIC
9← crossover$20,185$16.43$28,216$12,979.89$8.0KPFE
10$21,609$10.95$51,081$27,210.54$29.5KPFE

MGIC vs PFE: Complete Analysis 2026

MGICStock

Magic Software Enterprises Ltd. provides proprietary application development, business process integration, vertical software solutions, and information technologies (IT) outsourcing software services in Israel and internationally. The company's Software Services segment develops, markets, sells, and supports application platform, software applications, and business and process integration solutions and related services. Its IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, and supplemental outsourcing services. The company offers proprietary application platforms, such as Magic xpa for developing and deploying business applications; AppBuilder for building, deploying, and maintaining high-end and mainframe-grade business applications; Magic xpi for application integration; FactoryEye for virtualization of production data; BusinessEye for organizational business intelligence; and Magic SmartUX for cross-platform mobile business applications. It also provides vertical software solutions comprising Clicks, a software solution for healthcare providers; Leap, a software solution for business support systems; Hermes Cargo, a packaged software solution for managing air cargo ground handling; HR Pulse, a single-tenant software as a service tool; MBS Solution, a system for managing TV broadcast management; Nativ, a system for management of rehabilitation centers; and Mobisale, a system for sales and distribution field activities for consumer goods manufacturers and wholesalers. In addition, the company provides software maintenance, support, training, and consulting services. The company was formerly known as Mashov Software Export (1983) Ltd. and changed its name to Magic Software Enterprises Ltd. in 1991. Magic Software Enterprises Ltd. was incorporated in 1983 and is headquartered in Or Yehuda, Israel.

Full MGIC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MGIC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGIC vs SCHDMGIC vs JEPIMGIC vs OMGIC vs KOMGIC vs MAINMGIC vs JNJMGIC vs MRKMGIC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.